Serono Rebif Contract With Prime Bases Rebates On Comparative Total Cost Of Care, Patient Adherence
EMD Serono will pay Prime Therapeutics rebates on use of multiple sclerosis drug Rebif if patients have higher overall costs than those using a different MS drug and if patients maintain a specified level of adherence. Rebif is the third drug in the pharmacy benefit manager’s CareCentered Contract program.
You may also be interested in...
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.
FDA/CMS Summit speakers say they've yet to see any real interest from manufacturers in putting money at risk if their products don't meet outcome measures.